News from the healthcare data industry
As real-world evidence becomes ever more essential, a cancer health technology company that played a key role in modernizing 21st-century health data is capitalizing on its accomplishments in the U.S.—and...
By granting global partners access to real-world insights and synthetic data, the new partnership aims to accelerate research and inspire new therapy development to drive better patient outcomes July 28,...
By Tamra Sami Keeping innovation growing at a fast clip while retaining new global supply chain capacity built up during the pandemic were the main topics of discussion at the BIO...
Digital Front Door automates the true patient journey and accelerates RWE SAN DIEGO, July 28, 2022 /PRNewswire/ — Seqster PDM, Inc. (“Seqster“), the leader in patient-centric healthcare data technology announced a 3-year...
By Jordanna Jayne, Ph.D. Before product developers can more confidently design RWE studies and venture away from the traditional path of lengthy prospective studies, industry must overcome several challenges. This article...
SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) — Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care,...
Eugenio Zuccarelli, an innovation data scientist at Rhode Island-based CVS Health, didn’t set out on a career in AI because he wanted to work in healthcare. He simply wanted to do...
The COVID-19 pandemic has surfaced the potential and risks of linked real word datasets to accelerate and produce new improvements in public health. In this post, Matthew Franklin, Dan Howdon, Suzanne Mason, Tony Stone, Monica...
The gathering, convened by patient advocacy group Fight Colorectal Cancer, responded to President Biden’s call to improve screening and treatment options. Read More: https://www.outsourcing-pharma.com/Article/2022/07/26/cancer-moonshot-meeting-brings-together-survivors-leaders?utm_source=copyright&utm_medium=OnSite&utm_campaign=copyright
The scope of RWE’s use in developing and approving new medicines is pitting key healthcare stakeholders against each other. It’s been coming for years, but now it’s starting to bite....